Literature DB >> 9569959

A case of Guillain-Barré syndrome developed minimal change nephrotic syndrome simultaneously.

H Kitamura1, T Nakano, M Kakihara, M Nishino, K Isshiki, K Kawano, A Yamauchi, E Imai, T Kamada, H Abe.   

Abstract

A case who developed Guillain-Barré syndrome (GBS) and nephrotic syndrome (NS) simultaneously is reported. In this case, the onset of nephrotic change of proteinuria coincided with the development of the neurological disturbance. Analysis of renal biopsy by light, immunofluorescent and electron microscopy showed minor glomerular abnormalities. The occurrence of GBS in association with NS is rare, and moreover most cases in the previous reports had membranous nephropathy. Only 1 case had minimal change nephrotic syndrome (MCNS). To our knowledge, this is the first report of a case beneficially treated with glucocorticoids, suggesting that immune disorder may play an important role in the association between MCNS and GBS.

Entities:  

Mesh:

Year:  1998        PMID: 9569959     DOI: 10.1159/000013325

Source DB:  PubMed          Journal:  Am J Nephrol        ISSN: 0250-8095            Impact factor:   3.754


  4 in total

1.  Minimal change nephrotic syndrome with Guillain-Barré syndrome.

Authors:  Mohammad Ilyas; Asad Tolaymat
Journal:  Pediatr Nephrol       Date:  2003-11-25       Impact factor: 3.714

2.  Secondary membranous nephropathy associated with guillain-barré syndrome.

Authors:  Edward J Filippone; Mitul Kanzaria; Rodney Bell; Eric Newman; John L Farber
Journal:  Case Rep Nephrol Urol       Date:  2013-04-10

3.  Steroid-responsive polyradiculopathy in association with focal segmental glomerulosclerosis.

Authors:  Andrew R Chapman; Paul Gamble; Anne Marie Pollock; Nicola Joss
Journal:  Clin Kidney J       Date:  2013-08-26

4.  Inflammatory demyelinating neuropathies with focal segmental glomerulosclerosis: Two case reports.

Authors:  Yuhe Mao; Min Zhang; Shaojun Liu; Yunyu Xu; Jun Xue; Chuanming Hao; Lingyun Lai
Journal:  Medicine (Baltimore)       Date:  2018-12       Impact factor: 1.817

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.